Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Leuk Res Retrieve available abstracts of 311 articles: HTML format

Single Articles

February 2025
1. KOMROKJI Z, Ali NA, Xie Z, Chan O, et al
   Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).
   Leuk Res. 2025;150:107662.
   PubMed     Abstract available
   
   
   January 2025
2. YOSHIDA N, Hida A, Sakata R
   Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally.
   Leuk Res. 2025;150:107654.
   PubMed     Abstract available
   
   
   
3. YOSHIMITSU M
   Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
   Leuk Res. 2025;149:107653.
   PubMed     Abstract available
   
   
   
4. DENG A, Zhang F, Wang M, Jiang D, et al
   A novel KMT2A::DCP1A fusion gene in acute myeloid leukemia.
   Leuk Res. 2025;149:107645.
   PubMed    
   
   
   
5. EPSTEIN-PETERSON ZD, Gurumurthi A, Horwitz SM
   New treatments for adult T-cell leukemia/lymphoma.
   Leuk Res. 2025;149:107642.
   PubMed     Abstract available
   
   
   
6. FONTECHA MB, Del Rosario Anadon M, Lahitou IMM, Weich N, et al
   Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia.
   Leuk Res. 2025;149:107644.
   PubMed     Abstract available
   
   
   
7. WETERINGS DA, Rowan AG, Cook LB
   Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
   Leuk Res. 2025;148:107635.
   PubMed     Abstract available
   
   
   
8. WU H, Luo H, Wang M, Du Y, et al
   NAP1L5 promotes epithelial-mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia.
   Leuk Res. 2025;148:107623.
   PubMed     Abstract available
   
   
   December 2024
9. ZHAO R, Cui Y, Li D, Guo X, et al
   Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway.
   Leuk Res. 2024;149:107637.
   PubMed     Abstract available
   
   
   
10. SHAHZAD M, Iqbal Q, Amin MK, Irfan S, et al
    Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis.
    Leuk Res. 2024;148:107640.
    PubMed     Abstract available
    
    
    
11. LI M, Zhang S, Wei J, Liu M, et al
    The increase in the expression of circRNAs may contributes to a poor prognosis in acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2024;148:107639.
    PubMed     Abstract available
    
    
    
12. LI J, Fu S, Ye C, Li J, et al
    Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy.
    Leuk Res. 2024;148:107638.
    PubMed     Abstract available
    
    
    
13. KARUBE K, Sakihama S, Takatori M, Morichika K, et al
    Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
    Leuk Res. 2024;148:107634.
    PubMed     Abstract available
    
    
    
14. FUJI S
    Chemotherapy and allo-HSCT for young patients with aggressive ATL.
    Leuk Res. 2024;147:107596.
    PubMed     Abstract available
    
    
    November 2024
15. ROUZBAHANI M, Mousavi SA, Hajianfar G, Ghanaati A, et al
    Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques.
    Leuk Res. 2024;148:107619.
    PubMed     Abstract available
    
    
    
16. KIM JY, Vijayakumar KA, Cho GW
    Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock.
    Leuk Res. 2024;148:107620.
    PubMed     Abstract available
    
    
    
17. QIAN S, Gong J, Shen X, Chen M, et al
    Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study.
    Leuk Res. 2024;148:107621.
    PubMed     Abstract available
    
    
    
18. WANG X, Chen T
    Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report.
    Leuk Res. 2024;147:107616.
    PubMed    
    
    
    
19. MISHRA R, Calabrese C, Jain AG, Singh A, et al
    Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review.
    Leuk Res. 2024;146:107584.
    PubMed     Abstract available
    
    
    October 2024
20. ISFORT S, Gambacorti-Passerini C, Brummendorf TH, Smith BD, et al
    The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis.
    Leuk Res. 2024;147:107609.
    PubMed    
    
    
    
21. CHIEN KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, et al
    A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
    Leuk Res. 2024;147:107602.
    PubMed    
    
    
    
22. EL HAJJ H, Hermine O, Bazarbachi A
    Therapeutic advances for the management of adult T cell leukemia: Where do we stand?
    Leuk Res. 2024;147:107598.
    PubMed     Abstract available
    
    
    
23. LI T, Cui Q, Liu S, Li Z, et al
    Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
    Leuk Res. 2024;145:107569.
    PubMed     Abstract available
    
    
    September 2024
24. PRIYA, Garg M, Talwar R, Bharadwaj M, et al
    Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis.
    Leuk Res. 2024;147:107595.
    PubMed     Abstract available
    
    
    
25. CHEN R, AlHumaid M, Daher-Reyes G, Atenafu EG, et al
    Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience.
    Leuk Res. 2024;147:107586.
    PubMed     Abstract available
    
    
    
26. XIAO Y, Xiao L, Xu X, Guan X, et al
    Development and validation of a predictive model for tumor lysis syndrome in childhood acute lymphoblastic leukemia.
    Leuk Res. 2024;146:107587.
    PubMed     Abstract available
    
    
    
27. FAIZ AS, Guo S, Sridharan A, Lin Y, et al
    Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia.
    Leuk Res. 2024;146:107585.
    PubMed     Abstract available
    
    
    
28. ACHAR RK, McCormick BJ, Dworkin E, Geramita EM, et al
    Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.
    Leuk Res. 2024;146:107577.
    PubMed    
    
    
    
29. WU S, Liu F, Gai Y, Carter J, et al
    Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
    Leuk Res. 2024;144:107547.
    PubMed     Abstract available
    
    
    August 2024
30. DESAI A, Samara Y, Yang D, Ball B, et al
    Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.
    Leuk Res. 2024;145:107565.
    PubMed     Abstract available
    
    
    
31. DIAZ MARTINEZ JP, de Maraumont TA, Camacho LM, Garcia L, et al
    Cost-effectiveness of blinatumomab for the treatment of B?precursor acute lymphoblastic leukemia pediatric patients with high?risk first?relapse in Mexico.
    Leuk Res. 2024;145:107560.
    PubMed     Abstract available
    
    
    
32. CINGELOVA S, Mikuskova E, Demitrovicova L, Mikudova V, et al
    Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide.
    Leuk Res. 2024;145:107567.
    PubMed     Abstract available
    
    
    
33. FU Q, Wang Y, Liu H, Gao H, et al
    Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia.
    Leuk Res. 2024;145:107564.
    PubMed     Abstract available
    
    
    
34. TRAVAGLINI S, Silvestrini G, Attardi E, Fanciulli M, et al
    Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.
    Leuk Res. 2024;145:107568.
    PubMed     Abstract available
    
    
    
35. SHIMIZU H, Kato J, Tanoue S, Kimura SI, et al
    Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
    Leuk Res. 2024;144:107562.
    PubMed     Abstract available
    
    
    
36. BOISCLAIR S, Zhou E, Naing P, Thakur R, et al
    Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML.
    Leuk Res. 2024;143:107545.
    PubMed     Abstract available
    
    
    
37. GALIENI P, Troiani E, Picardi P, Angelini M, et al
    Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
    Leuk Res. 2024;143:107541.
    PubMed     Abstract available
    
    
    
38. EDWARDS K, Manoussaka M, Sayed U, Tsertsvadze T, et al
    MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL.
    Leuk Res. 2024;143:107540.
    PubMed     Abstract available
    
    
    
39. VIANNA DT, Reis Monte-Mor BDC, Noronha EP, Gutiyama LM, et al
    Molecular characterization of V(D)J rearrangements in immature acute leukemias.
    Leuk Res. 2024;143:107521.
    PubMed     Abstract available
    
    
    July 2024
40. CUI H, Ma Y, Han S, Zhang X, et al
    Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1.
    Leuk Res. 2024;144:107550.
    PubMed     Abstract available
    
    
    
41. MOLICA M, Perrone S, Rossi M, Giannarelli D, et al
    The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis.
    Leuk Res. 2024;144:107549.
    PubMed     Abstract available
    
    
    
42. KONG C, Wu M, Lu Q, Ke B, et al
    PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Leuk Res. 2024;144:107548.
    PubMed     Abstract available
    
    
    
43. MESTRUM SGC, Roanalis BYV, de Wit NCJ, Drent RJM, et al
    MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.
    Leuk Res. 2024;142:107520.
    PubMed     Abstract available
    
    
    June 2024
44. PARMAR K, Kundu R, Maiti A, Ball S, et al
    Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia.
    Leuk Res. 2024;144:107546.
    PubMed     Abstract available
    
    
    
45. XU Z, Zhang T, Hao J, Liu D, et al
    Identification of clonal relationship and prognostic significance in acute myeloid leukemia patients with concomitant increase in mast cells.
    Leuk Res. 2024;143:107539.
    PubMed    
    
    
    
46. SHIN DY, Park S, Jang E, Kong JH, et al
    Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
    Leuk Res. 2024;143:107542.
    PubMed     Abstract available
    
    
    
47. JESTRABEK H, Kohlhas V, Hallek M, Nguyen PH, et al
    Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia.
    Leuk Res. 2024;143:107531.
    PubMed     Abstract available
    
    
    
48. PANDA T, Rainchwar S, Singh R, Singh A, et al
    Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.
    Leuk Res. 2024;141:107506.
    PubMed     Abstract available
    
    
    May 2024
49. ODUTOLA PO, Olorunyomi PO, Olorunyomi I
    Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis.
    Leuk Res. 2024;142:107517.
    PubMed     Abstract available
    
    
    
50. RISUENO A, See WL, Bluemmert I, de Botton S, et al
    Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
    Leuk Res. 2024;140:107497.
    PubMed     Abstract available
    
    
    April 2024
51. SUN M, Li S, Liu Z, Ma S, et al
    Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
    Leuk Res. 2024;142:107507.
    PubMed     Abstract available
    
    
    
52. INDRAN T, Das T, Muirhead J, O'Brien M, et al
    Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+) donor chim
    Leuk Res. 2024;142:107504.
    PubMed     Abstract available
    
    
    
53. MOHEBBI A, Shahriyary F, Farrokhi V, Bandar B, et al
    A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2024;141:107505.
    PubMed     Abstract available
    
    
    
54. ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
    Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
    Leuk Res. 2024;141:107502.
    PubMed    
    
    
    
55. BERTON G, Sedaki B, Collomb E, Benachour S, et al
    Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
    Leuk Res. 2024;141:107500.
    PubMed     Abstract available
    
    
    
56. DONG S, Premnath N, Sadeghi N, Kainthla R, et al
    Racial and ethnic disparities in Acute Myeloid Leukemia: 15-year experience at a safety net hospital system.
    Leuk Res. 2024;141:107503.
    PubMed     Abstract available
    
    
    
57. ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
    Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study.
    Leuk Res. 2024;141:107501.
    PubMed     Abstract available
    
    
    
58. HU X, Cao P, Wang F, Wang T, et al
    Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation.
    Leuk Res. 2024;141:107499.
    PubMed     Abstract available
    
    
    
59. SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
    Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Leuk Res. 2024;139:107481.
    PubMed     Abstract available
    
    
    
60. MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
    Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
    Leuk Res. 2024;140:107498.
    PubMed     Abstract available
    
    
    March 2024
61. YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
    Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
    Leuk Res. 2024;140:107495.
    PubMed     Abstract available
    
    
    
62. MUTHIAH C, Narra R, Atallah E, Juan W, et al
    Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
    Leuk Res. 2024;140:107496.
    PubMed     Abstract available
    
    
    
63. BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al
    Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
    Leuk Res. 2024;140:107485.
    PubMed     Abstract available
    
    
    
64. IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al
    Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
    Leuk Res. 2024;140:107482.
    PubMed    
    
    
    
65. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
    Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
    Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
    PubMed     Abstract available
    
    
    
66. WAN CL, Huang YH, Huang SM, Xu YL, et al
    Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
    Leuk Res. 2024;139:107483.
    PubMed     Abstract available
    
    
    
67. PAN L, Li Y, Gao H, Lai X, et al
    Clinical features and management of germline CEBPA-mutated carriers.
    Leuk Res. 2024;138:107453.
    PubMed     Abstract available
    
    
    
68. SIDI Y, Dong C, Wu Y, Faller DV, et al
    A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
    Leuk Res. 2024;138:107465.
    PubMed     Abstract available
    
    
    February 2024
69. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Leuk Res. 2024;139:107467.
    PubMed     Abstract available
    
    
    
70. ZHONG S, Kurish H, Walchack R, Li H, et al
    Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2024;139:107468.
    PubMed     Abstract available
    
    
    
71. OSMAN AEG, Rets A, Patel AB
    KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
    Leuk Res. 2024;138:107466.
    PubMed    
    
    
    
72. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
    Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
    Leuk Res. 2024;138:107456.
    PubMed     Abstract available
    
    
    
73. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
    Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
    Leuk Res. 2024;138:107454.
    PubMed     Abstract available
    
    
    
74. GOULART H, Sastow D, Moshier E, Martin L, et al
    Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.
    Leuk Res. 2024;137:107452.
    PubMed     Abstract available
    
    
    
75. ELGHETANY MT, Patnaik MM, Khoury JD
    Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Leuk Res. 2024;137:107441.
    PubMed     Abstract available
    
    
    
76. RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al
    When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML.
    Leuk Res. 2024;137:107440.
    PubMed    
    
    
    January 2024
77. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
    Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
    Leuk Res. 2024;137:107439.
    PubMed    
    
    
    
78. OH I, Hatano K, Ikeda T, Toda Y, et al
    Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
    Leuk Res. 2024;137:107438.
    PubMed    
    
    
    
79. DIDI I, Alliot JM, Dumas PY, Vergez F, et al
    Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
    Leuk Res. 2024;136:107437.
    PubMed     Abstract available
    
    
    
80. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
    Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
    Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430.
    PubMed    
    
    
    
81. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
    VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
    Leuk Res. 2024;136:107432.
    PubMed    
    
    
    
82. KHANNA V, Lu R, Kumar J, Molina A, et al
    The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Leuk Res. 2024;136:107433.
    PubMed     Abstract available
    
    
    December 2023
83. NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al
    A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
    Leuk Res. 2023;135:107405.
    PubMed    
    
    
    November 2023
84. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
    Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
    Leuk Res. 2023;136:107429.
    PubMed    
    
    
    
85. URBINO I, Secreto C, Apolito V, Olivi M, et al
    Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
    Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421.
    PubMed    
    
    
    
86. ZHAO D, Zhou Q, Zarif M, Eladl E, et al
    AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
    Leuk Res. 2023;134:107376.
    PubMed     Abstract available
    
    
    October 2023
87. RAVINDRA A, Acharya L, Loeffler B, Mott S, et al
    Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2023;135:107407.
    PubMed     Abstract available
    
    
    
88. ANSARI F, Behfar M, Jafari L, Mohseni R, et al
    A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Leuk Res. 2023;135:107416.
    PubMed     Abstract available
    
    
    
89. ZHANG F, Du H, Hu C, Song Y, et al
    A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
    Leuk Res. 2023;135:107404.
    PubMed     Abstract available
    
    
    
90. SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al
    Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
    Leuk Res. 2023;133:107368.
    PubMed     Abstract available
    
    
    September 2023
91. JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al
    Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
    Leuk Res. 2023;135:107403.
    PubMed    
    
    
    
92. JAMY OH, Kasner M, Wall S, Ingram S, et al
    Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
    Leuk Res. 2023;134:107393.
    PubMed     Abstract available
    
    
    
93. GURNEY M, Greipp PT, Gliem T, Knudson R, et al
    TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
    Leuk Res. 2023;134:107391.
    PubMed    
    
    
    
94. SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al
    Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
    Leuk Res. 2023;134:107392.
    PubMed     Abstract available
    
    
    
95. PATEL SA, Bello E, Wilks A, Gerber JM, et al
    Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
    Leuk Res. 2023;134:107388.
    PubMed     Abstract available
    
    
    
96. HIRT CK, Padmanabha N, Michaels PD
    Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
    Leuk Res. 2023;132:107357.
    PubMed    
    
    
    
97. BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al
    Changing frontline AML treatment patterns from 2013 to 2022.
    Leuk Res. 2023;132:107354.
    PubMed     Abstract available
    
    
    
98. XIE W, Wang Z, Guo X, Guan H, et al
    MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10.
    Leuk Res. 2023;132:107350.
    PubMed     Abstract available
    
    
    August 2023
99. DE LA GARZA-SALAZAR F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, et al
    Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
    Leuk Res. 2023;133:107373.
    PubMed     Abstract available
    
    
    
100. KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al
     Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
     Leuk Res. 2023;133:107374.
     PubMed     Abstract available
     
     
     
101. OWEN C, Eisinga S, Banerji V, Johnson N, et al
     Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.
     Leuk Res. 2023;133:107372.
     PubMed     Abstract available
     
     
     
102. BOULIGNY IM, Murray G, Ho T, Doyel M, et al
     Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
     Leuk Res. 2023;134:107370.
     PubMed    
     
     
     
103. ZHAO ZY, Tang N, Lin LE
     A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
     Leuk Res. 2023;133:107369.
     PubMed     Abstract available
     
     
     
104. BHATTACHARJEE U, Jandial A, Singh C, Lekshmon KS, et al
     Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
     Leuk Res. 2023;133:107367.
     PubMed     Abstract available
     
     
     
105. JAIN T, Ware AD, Dalton WB, Pasca S, et al
     Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
     Leuk Res. 2023;131:107345.
     PubMed     Abstract available
     
     
     
106. HASSAN HT
     Antibody-drug conjugate [ADC] treatment of leukaemia.
     Leuk Res. 2023;131:107078.
     PubMed     Abstract available
     
     
     July 2023
107. STAHL M, Giblin G, Liu Y, Winer ES, et al
     Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
     Leuk Res. 2023;132:107351.
     PubMed     Abstract available
     
     
     
108. BRUNNER AM, Huggar D, Copher R, Zhou ZY, et al
     Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
     Leuk Res. 2023;132:107353.
     PubMed     Abstract available
     
     
     
109. HEGER JM, Boll B, Naendrup JH, Simon F, et al
     Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis.
     Leuk Res. 2023;132:107352.
     PubMed     Abstract available
     
     
     
110. DENG X, Zeng Y, Qiu X, Zhong M, et al
     CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/beta-catenin pathway.
     Leuk Res. 2023;130:107312.
     PubMed     Abstract available
     
     
     
111. KIRTEK T, Chen W, Laczko D, Bagg A, et al
     Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.
     Leuk Res. 2023;130:107309.
     PubMed     Abstract available
     
     
     June 2023
112. RATAJCZAK B, Przybylowicz-Chalecka A, Czerwinska-Rybak J, Kandula Z, et al
     The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
     Leuk Res. 2023;132:107349.
     PubMed     Abstract available
     
     
     
113. SHAIKH MR, Singh B, Halder R, Singh R, et al
     FLAG based v/s Standard 3 + 7 induction therapy in treatment naive Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
     Leuk Res. 2023;132:107346.
     PubMed     Abstract available
     
     
     
114. GUARANA M, Nucci M
     Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
     Leuk Res. 2023;131:107341.
     PubMed     Abstract available
     
     
     
115. MOORE JE, Bloom PC, Chu CC, Bruno JE, et al
     Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
     Leuk Res. 2023;129:107072.
     PubMed     Abstract available
     
     
     May 2023
116. KHANNA V, Azenkot T, Liu SQ, Gilbert J, et al
     Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
     Leuk Res. 2023;131:107331.
     PubMed    
     
     
     
117. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
     Corrigendum to "Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines" [Leukemia Res. 128, 107054].
     Leuk Res. 2023 May 29:107329. doi: 10.1016/j.leukres.2023.107329.
     PubMed    
     
     
     
118. BADE R, Banaszak LG, Osman F, Cabral P, et al
     Neighborhood disadvantage, insurance status, and molecular profiling of patients with acute myeloid leukemia.
     Leuk Res. 2023;131:107326.
     PubMed     Abstract available
     
     
     
119. MARTINEZ-CASTILLO M, Gomez-Romero L, Tovar H, Olarte-Carrillo I, et al
     Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
     Leuk Res. 2023;131:107325.
     PubMed     Abstract available
     
     
     
120. SALAMA H, Eldadah S, Omer MH, Alhejazi A, et al
     Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
     Leuk Res. 2023;130:107316.
     PubMed     Abstract available
     
     
     
121. WU X, Thisdelle J, Hou S, Fajardo-Despaigne JE, et al
     Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.
     Leuk Res. 2023;131:107315.
     PubMed     Abstract available
     
     
     
122. OYA S, Ozawa H, Maehiro Y, Nakamura T, et al
     Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
     Leuk Res. 2023;130:107313.
     PubMed    
     
     
     
123. ATCHLEY E, Weis TM, Derkach A, Galera PK, et al
     Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
     Leuk Res. 2023;130:107311.
     PubMed     Abstract available
     
     
     
124. WANG Y, Liu H, Wang H, Wu Y, et al
     Enhancing morphological analysis of peripheral blood cells in chronic lymphocytic leukemia with an artificial intelligence-based tool.
     Leuk Res. 2023;130:107310.
     PubMed     Abstract available
     
     
     
125. BALSAT M, Alcazer V, Etienne G, Huguet F, et al
     First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
     Leuk Res. 2023;130:107308.
     PubMed     Abstract available
     
     
     
126. EDMUND J, Thaliath LJ, Meleveedu K
     Acute myeloid leukemia in the medically unfit elderly patients.
     Leuk Res. 2023;130:107306.
     PubMed     Abstract available
     
     
     
127. ARCHIBALD WJ, Baran AM, Williams AM, Salloum RM, et al
     The role of splenectomy in management of splenic B-cell lymphomas.
     Leuk Res. 2023;128:107053.
     PubMed     Abstract available
     
     
     
128. SUN X, Bai Y, Li M, Li W, et al
     Differential effects of recombinant human thrombopoietin on clinical outcomes in CD7-positive and CD7-negative acute myeloid leukaemia.
     Leuk Res. 2023;128:107034.
     PubMed     Abstract available
     
     
     April 2023
129. TINAJERO J, Koller P, Ali H
     Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia.
     Leuk Res. 2023;129:107299.
     PubMed    
     
     
     
130. AIMAN W, Ali MA, Basit MA, Omar Z, et al
     Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
     Leuk Res. 2023;129:107077.
     PubMed     Abstract available
     
     
     
131. WILDE L, Porazzi P, Trotta R, De Dominici M, et al
     A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
     Leuk Res. 2023;129:107075.
     PubMed     Abstract available
     
     
     
132. OWEN C, Banerji V, Johnson N, Gerrie A, et al
     Corrigendum to "Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update" [Leukemia Research 125 (2023) 107016].
     Leuk Res. 2023 Apr 3:107073. doi: 10.1016/j.leukres.2023.107073.
     PubMed    
     
     
     
133. JINDRA P, Karas M, Lysak D, Sramek J, et al
     Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
     Leuk Res. 2023;127:107052.
     PubMed     Abstract available
     
     
     
134. MIRET M, Anderson A, Hindocha P, Cirneanu L, et al
     Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
     Leuk Res. 2023;127:107042.
     PubMed     Abstract available
     
     
     
135. KIRKIZLAR TA, Kirkizlar O, Demirci U, Umut A, et al
     Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
     Leuk Res. 2023;127:107043.
     PubMed     Abstract available
     
     
     March 2023
136. YI ES, Baek HJ, Ju HY, Kim SK, et al
     Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group.
     Leuk Res. 2023;129:107070.
     PubMed     Abstract available
     
     
     
137. DELIA M, Gagliardi VP, Carluccio P, Attolico I, et al
     Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
     Leuk Res. 2023;129:107069.
     PubMed    
     
     
     
138. CHEN S, Tao Y, Wang Q, Ren J, et al
     Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia.
     Leuk Res. 2023;128:107059.
     PubMed     Abstract available
     
     
     
139. CHANTEPIE SP, Mear JB, Briant AR, Vilque JP, et al
     Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.
     Leuk Res. 2023;129:107058.
     PubMed     Abstract available
     
     
     
140. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
     Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
     Leuk Res. 2023;128:107054.
     PubMed     Abstract available
     
     
     
141. KILIC GUNES E, Ozkurt ZN, Yildiz S, Ozet G, et al
     Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients.
     Leuk Res. 2023;128:107055.
     PubMed     Abstract available
     
     
     
142. LAPIETRA G, Limongi MZ, Buffolino S, Nanni M, et al
     Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
     Leuk Res. 2023;126:107035.
     PubMed    
     
     
     
143. JAHN J, Diamond B, Hsu J, Montoya S, et al
     Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.
     Leuk Res. 2023;126:107020.
     PubMed     Abstract available
     
     
     February 2023
144. BATALLER A, Chien KS, Sasaki K, Montalban-Bravo G, et al
     PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
     Leuk Res. 2023;127:107044.
     PubMed    
     
     
     
145. MAURILLO L, Spagnoli A, Candoni A, Papayannidis C, et al
     Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy.
     Leuk Res. 2023;127:107040.
     PubMed     Abstract available
     
     
     
146. YANG Z, Liu C, Hu Y, Liu H, et al
     Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
     Leuk Res. 2023;127:107039.
     PubMed    
     
     
     
147. PREMNATH N, Chung SS, Weinberg OK, Ikpefan R, et al
     Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
     Leuk Res. 2023;125:107001.
     PubMed     Abstract available
     
     
     January 2023
148. TARANTINI F, Cumbo C, Zagaria A, Anelli L, et al
     Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.
     Leuk Res. 2023;127:107023.
     PubMed     Abstract available
     
     
     
149. MOHAMMADI F, Rostami G, Hamid M, Shafiei M, et al
     Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
     Leuk Res. 2023;126:107021.
     PubMed     Abstract available
     
     
     
150. NABIL R, Abdellateif MS, Gamal H, Hassan NM, et al
     Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia.
     Leuk Res. 2023;126:107019.
     PubMed     Abstract available
     
     
     
151. OWEN C, Banerji V, Johnson N, Gerrie A, et al
     Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
     Leuk Res. 2023;125:107016.
     PubMed     Abstract available
     
     
     
152. HEEKUK P, Uhlemann AC, Jacobs SS, Mowbray C, et al
     Title: Obesogenic microbial signatures and the development of obesity in childhood acute lymphoblastic leukemia.
     Leuk Res. 2023;126:107017.
     PubMed     Abstract available
     
     
     
153. DEMINA I, Zerkalenkova E, Semchenkova A, Volchkov E, et al
     Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL.
     Leuk Res. 2023;125:107018.
     PubMed    
     
     
     
154. FUKUDA S, Matsuda N, Shoji T, Onishi C, et al
     The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD(+) cells via RUNX1.
     Leuk Res. 2023;124:106983.
     PubMed     Abstract available
     
     
     
155. RAMANAN R, Tiong IS, Ivey A, Ong DM, et al
     Cellular distribution of IDH mutations in AML during morphologic remission.
     Leuk Res. 2023;124:106993.
     PubMed     Abstract available
     
     
     December 2022
156. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
     Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
     Leuk Res. 2022;125:107004.
     PubMed     Abstract available
     
     
     
157. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
     Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
     Leuk Res. 2022;125:106998.
     PubMed    
     
     
     
158. ZHOU Q, Zhao D, Eladl E, Capo-Chichi JM, et al
     Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.
     Leuk Res. 2022;124:107002.
     PubMed     Abstract available
     
     
     
159. ABEDIN SM, Badar T, Gauger K, Michaelis LC, et al
     Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2022;123:106984.
     PubMed    
     
     
     
160. RAMIA DE CAP M, Wu LP, Pihan GA, Narayanan D, et al
     NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.
     Leuk Res. 2022;123:106965.
     PubMed    
     
     
     
161. GABRA MM, Chow JT, Kim T, Son MH, et al
     A 5-microRNA signature derived from core binding factor-AML is predictive in adult and childhood AML.
     Leuk Res. 2022;123:106968.
     PubMed    
     
     
     November 2022
162. COTTINGHAM AH, Baker LB, Hoffmann ML, Martin CE, et al
     We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death.
     Leuk Res. 2022;124:106994.
     PubMed     Abstract available
     
     
     
163. OERTLING E, Fuda F, Koduru P, Chen M, et al
     Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei.
     Leuk Res. 2022;124:106995.
     PubMed    
     
     
     
164. KING AC, Derkach A, Weis TM, Stump SE, et al
     Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
     Leuk Res. 2022;122:106929.
     PubMed    
     
     
     October 2022
165. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
     A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
     Leuk Res. 2022;123:106982.
     PubMed    
     
     
     
166. PARISI R, Cowen EA, Stoll JR, Zhu H, et al
     Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
     Leuk Res. 2022;123:106970.
     PubMed     Abstract available
     
     
     
167. KAYA Z, Keser E, Atalay E, Kayhan G, et al
     Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome.
     Leuk Res. 2022;123:106981.
     PubMed    
     
     
     
168. GANZEL C, Sun Z, Baslan T, Zhang Y, et al
     Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
     Leuk Res. 2022;123:106971.
     PubMed     Abstract available
     
     
     
169. FUJIWARA SI, Murahashi R, Nakashima H, Matsuoka S, et al
     Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
     Leuk Res. 2022;121:106951.
     PubMed     Abstract available
     
     
     
170. LI L, Hu X, Nkwocha J, Sharma K, et al
     Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells.
     Leuk Res. 2022;121:106944.
     PubMed    
     
     
     
171. NANAA A, He R, Viswanatha D, Nguyen P, et al
     Comparison between GATA2 and DDX41-mutated myeloid neoplasms.
     Leuk Res. 2022;121:106931.
     PubMed    
     
     
     
172. PODGORNIK H, Sucurovic S, Skerget M, Debeljak M, et al
     Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant.
     Leuk Res. 2022;121:106933.
     PubMed    
     
     
     
173. RAINCHWAR S, Halder R, Singh R, Mehta P, et al
     Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
     Leuk Res. 2022;121:106926.
     PubMed     Abstract available
     
     
     September 2022
174. DEFINA M, Lazzarotto D, Guolo F, Minetto P, et al
     Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
     Leuk Res. 2022;122:106963.
     PubMed    
     
     
     
175. MEENA JP, Pathak N, Gupta AK, Bakhshi S, et al
     Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia.
     Leuk Res. 2022;122:106954.
     PubMed     Abstract available
     
     
     
176. LAN X, Ruminy P, Bohers E, Rainville V, et al
     5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia.
     Leuk Res. 2022;123:106952.
     PubMed     Abstract available
     
     
     
177. MA S, Rosen ST, Winqvist M, Frankfurt O, et al
     Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
     Leuk Res. 2022;122:106945.
     PubMed     Abstract available
     
     
     
178. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
     Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
     Leuk Res. 2022;122:106946.
     PubMed     Abstract available
     
     
     
179. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
     Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].
     Leuk Res. 2022 Sep 2:106943. doi: 10.1016/j.leukres.2022.106943.
     PubMed    
     
     
     
180. QI K, Hu X, Yu X, Cheng H, et al
     Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
     Leuk Res. 2022;120:106920.
     PubMed     Abstract available
     
     
     August 2022
181. BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
     Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
     Leuk Res. 2022;122:106942.
     PubMed     Abstract available
     
     
     
182. GARCIA-VILLASENOR E, Cortes JE, Reyes-Cisneros OA, Fernandez-Gutierrez JA, et al
     Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
     Leuk Res. 2022;121:106935.
     PubMed     Abstract available
     
     
     
183. CHEN H, Xu LP, Zhang XH, Wang Y, et al
     Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
     Leuk Res. 2022;121:106930.
     PubMed     Abstract available
     
     
     
184. DHAKAL P, Lyden E, Joshi U, Pyakuryal A, et al
     Charlson comorbidity index predicts early mortality and overall survival in acute promyelocytic leukemia.
     Leuk Res. 2022;122:106927.
     PubMed    
     
     
     
185. ORTI G, Garcia-Gutierrez V, Bautista G, Ferrer-Marin F, et al
     Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia.
     Leuk Res. 2022;121:106923.
     PubMed    
     
     
     
186. MARLEY AR, Ryder JR, Turcotte LM, Spector LG, et al
     Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms.
     Leuk Res. 2022;121:106924.
     PubMed     Abstract available
     
     
     
187. KOLODRUBIEC J, Kozlowska M, Irga-Jaworska N, Sedek L, et al
     Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
     Leuk Res. 2022;121:106925.
     PubMed     Abstract available
     
     
     July 2022
188. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
     Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.
     Leuk Res. 2022;120:106919.
     PubMed     Abstract available
     
     
     
189. BARKHORDAR M, Kasaeian A, Janbabai G, Mousavi SA, et al
     Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-yea
     Leuk Res. 2022;120:106918.
     PubMed     Abstract available
     
     
     
190. ZHAO D, Zarif M, Eladl E, Capo-Chichi JM, et al
     NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
     Leuk Res. 2022;118:106869.
     PubMed     Abstract available
     
     
     
191. CHAUVET P, Nibourel O, Berthon C, Goursaud L, et al
     Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
     Leuk Res. 2022;118:106871.
     PubMed     Abstract available
     
     
     
192. LIU J, Qin W, Wang B, Wang Z, et al
     PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
     Leuk Res. 2022;118:106859.
     PubMed     Abstract available
     
     
     June 2022
193. LIPILKIN PV, Kulaeva ED, Mashkina EV
     Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
     Leuk Res. 2022;120:106910.
     PubMed     Abstract available
     
     
     
194. GAO X, Fan S, Zhang X
     MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression.
     Leuk Res. 2022;120:106906.
     PubMed     Abstract available
     
     
     
195. CHOJECKI AL, Arnall J, Boselli D, Patel R, et al
     Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
     Leuk Res. 2022;119:106904.
     PubMed    
     
     
     
196. DUMAS PY, Bertoli S, Bonmati C, Carre M, et al
     Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.
     Leuk Res. 2022;120:106901.
     PubMed    
     
     
     
197. FRISCH A, Aumann S, Zuckerman T, Leiba R, et al
     Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study.
     Leuk Res. 2022;119:106902.
     PubMed     Abstract available
     
     
     
198. OTHMAN T, Moskoff BN, Ho G, Tenold ME, et al
     Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
     Leuk Res. 2022;119:106885.
     PubMed     Abstract available
     
     
     
199. TATARIAN J, Byrd K, Male HJ, Lin TL, et al
     Central nervous system involvement in adult acute myeloid leukemia patients.
     Leuk Res. 2022;118:106882.
     PubMed    
     
     
     
200. HASHIMOTO H, Gungor D, Krickeberg N, Schmitt J, et al
     TH1 cytokines induce senescence in AML.
     Leuk Res. 2022;117:106842.
     PubMed     Abstract available
     
     
     May 2022
201. KIM K, Bazinet A, Loghavi S, Konopleva M, et al
     Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
     Leuk Res. 2022;119:106884.
     PubMed    
     
     
     
202. GOSWAMI S, Chiang CL, Zapolnik K, Nunes J, et al
     ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
     Leuk Res. 2022;118:106872.
     PubMed    
     
     
     
203. STEIDL C, Aroldi A, Mologni L, Crespiatico I, et al
     Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
     Leuk Res. 2022;118:106861.
     PubMed     Abstract available
     
     
     
204. TASHAKORI M, Wang W, Kadia TM, Daver NG, et al
     Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
     Leuk Res. 2022;118:106860.
     PubMed     Abstract available
     
     
     
205. KIM T, Ahn JS, Son MH, Novitzky-Basso I, et al
     Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
     Leuk Res. 2022;118:106858.
     PubMed     Abstract available
     
     
     
206. KARBALIVAND M, Almada LL, Ansell SM, Fernandez-Zapico ME, et al
     MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
     Leuk Res. 2022;116:106841.
     PubMed     Abstract available
     
     
     
207. NORVILAS R, Batiuskaite R, Dirse V, Semaskeviciene R, et al
     Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL.
     Leuk Res. 2022;116:106825.
     PubMed     Abstract available
     
     
     April 2022
208. ARORA S, Zainaldin C, Bathini S, Gupta U, et al
     Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
     Leuk Res. 2022;117:106844.
     PubMed     Abstract available
     
     
     
209. BAI H, Zhang Q, Zhang S, Wang J, et al
     Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.
     Leuk Res. 2022;117:106843.
     PubMed     Abstract available
     
     
     March 2022
210. NGUYEN PC, Donati V, Vassili C, Grigg AP, et al
     Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.
     Leuk Res. 2022 Mar 27:106837. doi: 10.1016/j.leukres.2022.106837.
     PubMed    
     
     
     
211. SHEHATA AMF, Gohar SF, Muharram NM, Eldin SMK, et al
     LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients.
     Leuk Res. 2022;116:106838.
     PubMed     Abstract available
     
     
     
212. TRIGUERO A, Xicoy B, Zamora L, Jimenez MJ, et al
     Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
     Leuk Res. 2022;116:106836.
     PubMed     Abstract available
     
     
     
213. JELLOUL FZ, Yang R, Garces S, Kanagal-Shamanna R, et al
     Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
     Leuk Res. 2022;116:106827.
     PubMed     Abstract available
     
     
     
214. BHREATHNACH U, Doherty D, Murphy K, Flynn CM, et al
     Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia.
     Leuk Res. 2022;116:106823.
     PubMed    
     
     
     
215. KAMATH-LOEB AS, Shen JC, Schmitt MW, Kohrn BF, et al
     Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.
     Leuk Res. 2022;115:106822.
     PubMed     Abstract available
     
     
     
216. HERNANDEZ-BOLUDA JC, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, et al
     Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
     Leuk Res. 2022;115:106821.
     PubMed     Abstract available
     
     
     
217. WANG X, Bajpai AK, Gu Q, Centeno A, et al
     A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.
     Leuk Res. 2022;114:106804.
     PubMed     Abstract available
     
     
     February 2022
218. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
     Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
     Leuk Res. 2022 Feb 23:106811. doi: 10.1016/j.leukres.2022.106811.
     PubMed    
     
     
     
219. ROSTAMI M, Kharajo RS, Parsa-Kondelaji M, Ayatollahi H, et al
     Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia.
     Leuk Res. 2022;115:106807.
     PubMed     Abstract available
     
     
     
220. NUHOGLU KANTARCI E, Eskazan AE
     Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
     Leuk Res. 2022;114:106808.
     PubMed     Abstract available
     
     
     
221. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
     Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
     Leuk Res. 2022;114:106803.
     PubMed     Abstract available
     
     
     
222. KUSNE Y, Xie Z, Patnaik MM
     Clonal hematopoiesis: Molecular and clinical implications.
     Leuk Res. 2022;113:106787.
     PubMed     Abstract available
     
     
     
223. CHORNENKI NLJ, Siegal DM, Qamar K, Woolgar S, et al
     Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
     Leuk Res. 2022;113:106788.
     PubMed    
     
     
     January 2022
224. PARK H, Kang S, Kim I, Kim S, et al
     The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.
     Leuk Res. 2022;114:106791.
     PubMed     Abstract available
     
     
     
225. THOMAS JW, Jamy O, Shah MV, Vachhani P, et al
     Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
     Leuk Res. 2022;112:106770.
     PubMed     Abstract available
     
     
     
226. SORIGUE M, Arenillas L, Xicoy B, Andrade-Campos M, et al
     Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis.
     Leuk Res. 2022;112:106771.
     PubMed    
     
     
     
227. ALAYED K, Meyerson HJ
     Decreased CD177(pos) neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations.
     Leuk Res. 2022;112:106752.
     PubMed     Abstract available
     
     
     
228. PARKER C, Ayton D, Zomer E, Liew D, et al
     Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system.
     Leuk Res. 2022;112:106748.
     PubMed     Abstract available
     
     
     December 2021
229. SHERBAN A, Raanani P, Gurion R, Wolach O, et al
     Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
     Leuk Res. 2021;113:106773.
     PubMed     Abstract available
     
     
     
230. WEBSTER JA, Robinson TM, Blackford AL, Warlick E, et al
     A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
     Leuk Res. 2021;111:106737.
     PubMed     Abstract available
     
     
     
231. GAJZER D, Logothetis CN, Sallman DA, Calon G, et al
     MYC overexpression is associated with an early disease progression from MDS to AML.
     Leuk Res. 2021;111:106733.
     PubMed     Abstract available
     
     
     
232. OBENG-KUSI M, MacDonald K, van Lierde MA, Lee CS, et al
     No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
     Leuk Res. 2021;111:106734.
     PubMed     Abstract available
     
     
     
233. KOTA V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, et al
     Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias.
     Leuk Res. 2021;111:106690.
     PubMed     Abstract available
     
     
     
234. BAYRAK AG, Daglar Aday A, Yavuz AS, Nalcaci M, et al
     Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
     Leuk Res. 2021;111:106725.
     PubMed     Abstract available
     
     
     
235. MCBRIDE A, Daniel S, Driessen MT, Szende A, et al
     Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
     Leuk Res. 2021;111:106671.
     PubMed     Abstract available
     
     
     
236. BORSKY M, Hrabcakova V, Novotna J, Brychtova Y, et al
     Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
     Leuk Res. 2021;111:106684.
     PubMed     Abstract available
     
     
     November 2021
237. KAIVERS J, Peters J, Rautenberg C, Schroeder T, et al
     The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.
     Leuk Res. 2021;112:106757.
     PubMed     Abstract available
     
     
     
238. PERMIKIN Z, Popov A, Verzhbitskaya T, Riger T, et al
     Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
     Leuk Res. 2021;112:106758.
     PubMed    
     
     
     
239. SREEDHARANUNNI S, Jamwal M, Balakrishnan A, Aravindan AV, et al
     Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
     Leuk Res. 2021;112:106753.
     PubMed    
     
     
     
240. CIROVIC A, Cirovic A
     Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia.
     Leuk Res. 2021;112:106755.
     PubMed     Abstract available
     
     
     
241. NORSKOV KH, Fridthjof K, Kampmann P, Dunweber A, et al
     A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.
     Leuk Res. 2021;112:106756.
     PubMed     Abstract available
     
     
     
242. KEE KM, Kim SH, Yang SY, Shin JU, et al
     Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
     Leuk Res. 2021;112:106754.
     PubMed     Abstract available
     
     
     
243. MIRFAKHRAIE R, Noorazar L, Mohammadian M, Hajifathali A, et al
     Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.
     Leuk Res. 2021;112:106751.
     PubMed     Abstract available
     
     
     
244. LIESVELD JL, Baran A, Azadniv M, Misch H, et al
     A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.
     Leuk Res. 2021;112:106749.
     PubMed     Abstract available
     
     
     
245. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
     Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
     Leuk Res. 2021;111:106747.
     PubMed    
     
     
     
246. HUSELTON E, Rettig MP, Campbell K, Cashen AF, et al
     Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
     Leuk Res. 2021;110:106713.
     PubMed     Abstract available
     
     
     
247. WONG R, Nguyen A, Wang X, Chong L, et al
     Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling.
     Leuk Res. 2021;110:106712.
     PubMed    
     
     
     
248. AN L, Li X, Yang J
     MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12.
     Leuk Res. 2021;110:106653.
     PubMed     Abstract available
     
     
     October 2021
249. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
     Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
     Leuk Res. 2021;111:106736.
     PubMed     Abstract available
     
     
     
250. CHOW S, Tang K, Al-Abri M, Hall V, et al
     RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2021;111:106735.
     PubMed    
     
     
     
251. KANNAN KK, Vellanki P, Isom S, Tawfik B, et al
     Re-induction therapy in adult patients with acute myeloid leukemia with
     Leuk Res. 2021;111:106731.
     PubMed    
     
     
     
252. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
     Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
     Leuk Res. 2021;111:106729.
     PubMed     Abstract available
     
     
     
253. KALEKA G, Schiller G
     Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
     Leuk Res. 2021;112:106732.
     PubMed     Abstract available
     
     
     
254. PADMAKUMAR D, Chandraprabha VR, Gopinath P, Vimala Devi ART, et al
     A concise review on the molecular genetics of acute myeloid leukemia.
     Leuk Res. 2021;111:106727.
     PubMed     Abstract available
     
     
     
255. PARK H, Kim I, Kim HJ, Shin DY, et al
     Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
     Leuk Res. 2021;111:106728.
     PubMed     Abstract available
     
     
     
256. MARTINEZ-VERBO L, Estrada N, Cabezon M, Palomo L, et al
     Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
     Leuk Res. 2021;111:106726.
     PubMed    
     
     
     
257. LIM K, Thompson-Peach C, Thomas D
     Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency.
     Leuk Res. 2021;109:106644.
     PubMed     Abstract available
     
     
     September 2021
258. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
     Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
     Leuk Res. 2021;110:106702.
     PubMed     Abstract available
     
     
     
259. ESFANDBOD M, Enshaei M, Monzavi SM, Kabootari M, et al
     Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
     Leuk Res. 2021;111:106703.
     PubMed     Abstract available
     
     
     
260. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
     Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
     Leuk Res. 2021;110:106707.
     PubMed     Abstract available
     
     
     
261. DU X, Liu H, Yang C, Shi X, et al
     LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
     Leuk Res. 2021;110:106706.
     PubMed     Abstract available
     
     
     
262. ALVAREZ N, Rodriguez-Garcia A, Morales ML, Gutierrez M, et al
     Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
     Leuk Res. 2021;108:106613.
     PubMed    
     
     
     
263. ALEISSA MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, et al
     Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
     Leuk Res. 2021;108:106610.
     PubMed     Abstract available
     
     
     
264. LINCH DC, Hills RK, Gilkes A, Burnett AK, et al
     Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
     Leuk Res. 2021;108:106553.
     PubMed     Abstract available
     
     
     August 2021
265. YU J, Du Y, Jalil A, Ahmed Z, et al
     Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
     Leuk Res. 2021;110:106701.
     PubMed     Abstract available
     
     
     
266. ABRAMENKO I, Bilous N, Chumak A, Kryachok I, et al
     The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
     Leuk Res. 2021;110:106686.
     PubMed     Abstract available
     
     
     
267. DARASKEVICIUS J, Everatt V, Vaitekenaite V, Ringeleviciute U, et al
     Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
     Leuk Res. 2021;111:106692.
     PubMed    
     
     
     
268. RAHIMI Z, Ghorbani Z, Motamed H, Jalilian N, et al
     Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
     Leuk Res. 2021;111:106691.
     PubMed     Abstract available
     
     
     
269. YOUNG PE, Kanagal-Shamanna R, Hu S, Tang G, et al
     Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
     Leuk Res. 2021;111:106685.
     PubMed    
     
     
     
270. GOWIN K, Skerget S, Keats JJ, Mikhael J, et al
     Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
     Leuk Res. 2021;111:106687.
     PubMed     Abstract available
     
     
     
271. GUPTA SK, Bakhshi S, Kamal VK, Gupta R, et al
     Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
     Leuk Res. 2021;111:106683.
     PubMed     Abstract available
     
     
     July 2021
272. PLESA A, Roumier C, Gutrin J, Larcher MV, et al
     Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
     Leuk Res. 2021;111:106673.
     PubMed    
     
     
     
273. MA CE, Ghosh S, Leyshon C, Blosser N, et al
     Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
     Leuk Res. 2021;111:106674.
     PubMed     Abstract available
     
     
     
274. ALSHEMMARI SH, Hamdah A, Pandita R, Kunhikrishnan A, et al
     Chronic lymphocytic leukemia in a young population.
     Leuk Res. 2021;110:106668.
     PubMed     Abstract available
     
     
     
275. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
     Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
     Leuk Res. 2021;110:106666.
     PubMed     Abstract available
     
     
     
276. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
     Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
     Leuk Res. 2021;110:106665.
     PubMed     Abstract available
     
     
     
277. SMITH MR, Cronin JF, Weiss RF
     Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
     Leuk Res. 2021;110:106663.
     PubMed     Abstract available
     
     
     
278. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
     The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
     Leuk Res. 2021;110:106662.
     PubMed    
     
     
     
279. IBRAHIM M, Chen R, Vegel A, Panse K, et al
     Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen.
     Leuk Res. 2021;106:106583.
     PubMed    
     
     
     
280. GLASS JL, Derkach A, Hilden P, King A, et al
     Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
     Leuk Res. 2021;106:106569.
     PubMed     Abstract available
     
     
     June 2021
281. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
     Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
     Leuk Res. 2021;109:106650.
     PubMed    
     
     
     
282. CHENG L, Zeng S, Yan D, Tu L, et al
     Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
     Leuk Res. 2021;109:106649.
     PubMed     Abstract available
     
     
     
283. ZHANG Y, Feng S
     The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Leuk Res. 2021;109:106647.
     PubMed     Abstract available
     
     
     
284. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
     miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
     Leuk Res. 2021;109:106643.
     PubMed     Abstract available
     
     
     
285. GUPTA SK, Singh P, Chhabra R, Verma M, et al
     Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
     Leuk Res. 2021;109:106641.
     PubMed     Abstract available
     
     
     
286. HUNTER AM, Al Ali N, Mai A, Shah S, et al
     Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
     Leuk Res. 2021;109:106640.
     PubMed    
     
     
     
287. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
     Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
     Leuk Res. 2021;109:106612.
     PubMed     Abstract available
     
     
     
288. SONG J, Shang B, Pei Y, Shi M, et al
     A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
     Leuk Res. 2021;109:106638.
     PubMed     Abstract available
     
     
     
289. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
     Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
     Leuk Res. 2021;109:106628.
     PubMed     Abstract available
     
     
     
290. CHANDRA SEKARAN U, Grove CS
     Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
     Leuk Res. 2021;105:106572.
     PubMed    
     
     
     
291. MIYAUCHI J, Kawaguchi H
     The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
     Leuk Res. 2021;105:106570.
     PubMed     Abstract available
     
     
     May 2021
292. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
     Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
     Leuk Res. 2021;108:106627.
     PubMed     Abstract available
     
     
     
293. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
     Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
     Leuk Res. 2021;108:106616.
     PubMed     Abstract available
     
     
     
294. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
     Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
     Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.
     PubMed    
     
     
     
295. ALI H, Salhotra A, Stein AS, Nakamura R, et al
     Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
     Leuk Res. 2021;104:106579.
     PubMed    
     
     
     
296. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
     Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
     Leuk Res. 2021;104:106541.
     PubMed    
     
     
     April 2021
297. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
     Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
     Leuk Res. 2021;107:106603.
     PubMed     Abstract available
     
     
     
298. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
     High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
     Leuk Res. 2021;107:106604.
     PubMed     Abstract available
     
     
     
299. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
     WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
     Leuk Res. 2021;108:106587.
     PubMed    
     
     
     
300. VACHHANI P, Baron J, Freyer CW, Miller A, et al
     A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
     Leuk Res. 2021;107:106588.
     PubMed     Abstract available
     
     
     
301. CHEN P, Redd L, Schmidt Y, Koduru P, et al
     MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
     Leuk Res. 2021;106:106584.
     PubMed     Abstract available
     
     
     
302. PETRICK L, Imani P, Perttula K, Yano Y, et al
     Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
     Leuk Res. 2021;106:106585.
     PubMed     Abstract available
     
     
     
303. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
     Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
     Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.
     PubMed    
     
     
     
304. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
     The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
     Leuk Res. 2021;106:106567.
     PubMed    
     
     
     
305. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
     Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
     Leuk Res. 2021;103:106540.
     PubMed     Abstract available
     
     
     March 2021
306. PARK S, Choi EJ, Lee H, Jo DY, et al
     Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
     Leuk Res. 2021;105:106578.
     PubMed     Abstract available
     
     
     
307. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
     A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
     Leuk Res. 2021;105:106573.
     PubMed     Abstract available
     
     
     
308. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
     Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
     Leuk Res. 2021;104:106571.
     PubMed    
     
     
     
309. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
     Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
     Leuk Res. 2021;105:106568.
     PubMed     Abstract available
     
     
     
310. NI J, Hong J, Li Q, Zeng Q, et al
     Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
     Leuk Res. 2021;105:106564.
     PubMed     Abstract available
     
     
     
311. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
     Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
     Leuk Res. 2021;102:106523.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.